TESARO Inc (NASDAQ:TSRO) was the recipient of some unusual options trading activity on Friday. Investors acquired 4,766 call options on the stock. This represents an increase of approximately 1,698% compared to the average volume of 265 call options.

A number of equities research analysts recently weighed in on TSRO shares. BidaskClub upgraded shares of TESARO from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. Cann restated a “buy” rating and issued a $199.00 target price on shares of TESARO in a report on Friday, September 8th. Citigroup restated a “buy” rating and issued a $216.00 target price on shares of TESARO in a report on Monday, September 11th. Oppenheimer restated a “buy” rating and issued a $199.00 target price on shares of TESARO in a report on Sunday, September 10th. Finally, Wedbush restated an “outperform” rating and issued a $160.00 target price on shares of TESARO in a report on Monday, September 11th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $159.39.

In other news, SVP Martin H. Jr. Huber sold 829 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Martin H. Jr. Huber sold 592 shares of the company’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the completion of the sale, the senior vice president now owns 6,943 shares in the company, valued at approximately $823,439.80. The disclosure for this sale can be found here. 34.60% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. increased its stake in TESARO by 5.7% in the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after buying an additional 195,590 shares during the last quarter. Vanguard Group Inc. grew its position in shares of TESARO by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock valued at $416,537,000 after acquiring an additional 62,104 shares during the period. State Street Corp grew its position in shares of TESARO by 17.9% during the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock valued at $163,496,000 after acquiring an additional 177,057 shares during the period. Janus Henderson Group PLC grew its position in shares of TESARO by 24.9% during the 3rd quarter. Janus Henderson Group PLC now owns 895,556 shares of the biopharmaceutical company’s stock valued at $115,616,000 after acquiring an additional 178,406 shares during the period. Finally, BB Biotech AG grew its position in shares of TESARO by 6.5% during the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock valued at $122,796,000 after acquiring an additional 53,408 shares during the period.

Shares of TESARO (NASDAQ TSRO) opened at $76.90 on Wednesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35. TESARO has a one year low of $76.74 and a one year high of $192.94.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The firm had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The company’s revenue for the quarter was up 740.3% on a year-over-year basis. During the same quarter last year, the business posted ($1.72) EPS. equities analysts forecast that TESARO will post -8.17 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Stock Traders Buy High Volume of TESARO Call Options (TSRO)” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/stock-traders-buy-high-volume-of-tesaro-call-options-tsro/1773668.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.